VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Costa Rica is facing a growing obesity crisis, with two-thirds of adults overweight or obese. A longtime expat reflects on ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

A new algorithm enables smartwatch fitness trackers to more accurately monitor energy expenditure of people with obesity ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Individuals with MASLD with a lean vs nonlean body type have increased mortality and cardiovascular disease, among other outcomes.

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

A new study reports that measurements that detect body fat are a more accurate predictor of mortality risk than body mass ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...